ATHE
$3.34
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia.
Recent News
Alterity Therapeutics Limited's (ASX:ATH) Path To Profitability
With the business potentially at an important milestone, we thought we'd take a closer look at Alterity Therapeutics...
Alterity Says Data Showed Potential Multiple System Atrophy Drug Slowed Disease Progression in Phase 2 Study
Alterity Therapeutics (ATHE) said Thursday that data from a 77-patient phase 2 clinical trial of its
Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434
Alterity Therapeutics Limited (NASDAQ:ATHE) is one of the best performing ASX stocks in 2025. On September 15, the company shared data from its Phase 2 clinical trial of the drug ATH434-201 at the American Neurological Association Annual Meeting in Baltimore. The clinical trial involved people with Multiple System Atrophy (MSA), a rare brain condition that […]
We Think Alterity Therapeutics (ASX:ATH) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, Alterity...
Alterity Therapeutics Limited (ATHE) Announces Positive Topline Data From Phase 2 Trial of ATH434 in Multiple System Atrophy
Alterity Therapeutics Limited (NASDAQ:ATHE) is among the 12 Best Australian Stocks to Buy Right Now. The company recently reported positive topline data from an open-label Phase 2 clinical trial of ATH434-202 in individuals with multiple system atrophy (MSA). The trial involved evaluating patients with more advanced disease than studied earlier in the double-blind Phase 2 […]